Italia markets closed

Fresh Tracks Therapeutics, Inc. (FRTX)

Other OTC - Other OTC Prezzo differito. Valuta in USD.
Aggiungi a watchlist
0,9101-0,0105 (-1,14%)
Alla chiusura: 01:02PM EDT
Schermo intero
I prezzi di scambio non provengono da tutti i mercati
Chiusura precedente0,9206
Aperto0,9101
Denaro0,0000 x 1800
Lettera0,0000 x 3000
Min-Max giorno0,9101 - 0,9206
Intervallo di 52 settimane0,4500 - 1,1000
Volume795
Media Volume14.396
Capitalizzazione5,436M
Beta (5 anni mensile)0,49
Rapporto PE (ttm)N/D
EPS (ttm)-1,0600
Prossima data utili08 mag 2024 - 13 mag 2024
Rendimento e dividendo (futuro)N/D (N/D)
Data ex dividendoN/D
Stima target 1AN/D
  • GlobeNewswire

    Fresh Tracks Therapeutics Announces Board Approval of Plan of Liquidation and Dissolution

    Company intends to make cash distributions currently estimated to be between $5 million and $7 million, or $0.84 to $1.17 per share, to shareholders following shareholder approval and the filing of the certificate of dissolutionBOULDER, Colo., Sept. 19, 2023 (GLOBE NEWSWIRE) -- Fresh Tracks Therapeutics, Inc. (the “Company” or “Fresh Tracks”) (Nasdaq: FRTX) today announced that, after conducting an extensive potential strategic alternatives process and careful consideration of the outcomes of th

  • GlobeNewswire

    Fresh Tracks Therapeutics Reports Second Quarter 2023 Financial Results and Provides Corporate Update

    Strengthened current cash position to approximately $15 million as of July 31, 2023 as a result of sale of future rights to event-based milestone and earnout payments on net sales of sofpironium bromide to Botanix SB Inc. Board continues to evaluate strategic alternatives for the Company to maximize shareholder value BOULDER, Colo., Aug. 11, 2023 (GLOBE NEWSWIRE) -- Fresh Tracks Therapeutics, Inc. (the “Company” or “Fresh Tracks”) (Nasdaq: FRTX), a clinical-stage pharmaceutical company striving

  • GlobeNewswire

    Fresh Tracks Announces $8.25 Million Buyout of Its Right to Receive Future Sofpironium Bromide Payments from Botanix

    Strengthens cash position as Company continues to evaluate strategic options to maximize shareholder valueBOULDER, Colo., July 21, 2023 (GLOBE NEWSWIRE) -- Fresh Tracks Therapeutics, Inc. (the “Company” or “Fresh Tracks”) (Nasdaq: FRTX), a clinical-stage pharmaceutical company striving to transform patient lives by developing innovative and differentiated prescription therapeutics for the treatment of autoimmune, inflammatory, and other debilitating diseases, today announced it has entered into